Finance

Lists
500660:BOM
GlaxoSmithKline Pharmaceuticals Ltd
2 567,25 INR
+1,75%
(+44,25) 1D
16-окт., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500660...
Open
2 527,25 INR
High
2 572,40 INR
Low
2 527,25 INR
Mkt. cap
434,71 млд
Avg. vol.
5,03 миң
Volume
2,37 миң
Dividend
2,22%
Quarterly dividend
14,25 INR
Ex-dividend date
2026-ж., 29-май
P/E ratio
40,72
52-wk high
3 121,10 INR
52-wk low
2 088,00 INR
EPS
63,05 INR
Shares outstanding
169,41 млн
No. of employees
3 миң
Open
2 527,25 INR
High
2 572,40 INR
Low
2 527,25 INR
Mkt. cap
434,71 млд
Avg. vol.
5,03 миң
Volume
2,37 миң
Dividend
2,22%
Quarterly dividend
14,25 INR
Ex-dividend date
2026-ж., 29-май
P/E ratio
40,72
52-wk high
3 121,10 INR
52-wk low
2 088,00 INR
EPS
63,05 INR
Shares outstanding
169,41 млн
No. of employees
3 миң
News stories
From web sources and news partners
Profile
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
About GlaxoSmithKline Pharmaceuticals Ltd
CEO-
Employees3,1 миң
Founded1924-ж., 13-ноя.
Headquarters-
SectorPharmaceutical industry
Last report
2026-ж., 3-авг.
Fiscal period
Q1 2027
14,00 INR / 13,90 INR
+0,72%beat
Revenue / Est. (INR)
9,38 млд / 9,11 млд
+3,00%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
9,80 млд
10,41 млд
9,95 млд
9,38 млд
Cost of goods sold
3,56 млд
3,64 млд
3,69 млд
3,28 млд
Cost of revenue
3,56 млд
3,64 млд
3,69 млд
3,28 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,38 млд
1,52 млд
2,95 млд
1,59 млд
Operating expense
3,06 млд
3,26 млд
2,84 млд
3,31 млд
Total operating expenses
6,62 млд
6,90 млд
6,53 млд
6,59 млд
Operating income
3,18 млд
3,51 млд
3,43 млд
2,80 млд
Other non operating income
335,70 млн
321,20 млн
-1,09 млд
437,60 млн
EBT including unusual items
3,54 млд
4,00 млд
3,73 млд
3,22 млд
EBT excluding unusual items
3,51 млд
3,82 млд
2,94 млд
3,22 млд
Income tax expense
965,10 млн
1,04 млд
952,41 млн
852,70 млн
Effective tax rate
27,26%
26,08%
25,53%
26,44%
Other operating expenses
1,51 млд
1,54 млд
-236,82 млн
1,56 млд
Net income
2,57 млд
2,96 млд
2,78 млд
2,37 млд
Net profit margin
26,28%
28,39%
27,92%
25,27%
Earnings per share
-
-
-
14,00
Interest and investment income
-
-
657,30 млн
-
Interest expense
-5,10 млн
-11,90 млн
-6,12 млн
-9,70 млн
Net interest expenses
-5,10 млн
-11,90 млн
651,18 млн
-9,70 млн
Depreciation and amortization charges
174,30 млн
203,20 млн
131,74 млн
158,40 млн
EBITDA
3,35 млд
3,61 млд
3,52 млд
2,89 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору